Chemotherapy might help cancer vaccines work

Chemotherapy given in conjunction with cancer vaccines may boost the immune system’s response, potentially improving the effectiveness of this promising type of cancer therapy, according to a study by researchers in the Duke Comprehensive Cancer Center.

“Chemotherapy first knocks out T regulatory cells that suppress immune function and we speculated that this might have a complementary effect when used in conjunction with vaccines, which work by boosting immune function,” said Timothy Clay, Ph.D., a researcher at Duke and a lead investigator on this study. “We tested this theory both pre-clinically and in patients who were part of a vaccine trial at Duke for gastrointestinal cancers, and found that our hypothesis seemed to be true.”

The researchers will present their findings at the annual American Society of Clinical Oncology meeting in Chicago, on May 31. The study was funded by the National Cancer Institute.

Researchers used a drug called denileukin diftitox (ONTAK) for this study; the drug is routinely used to treat a type of lymphoma and is known to deplete certain types of immune cells including the T regulatory cells that “put the brakes” on immune function. They speculated it might facilitate better immune responses to a cancer vaccine.

“In the lab work, we definitely saw a heightened immune response when we used the denileukin diftitox in conjunction with the vaccine. The vaccine we used targets a protein found in gastrointestinal tumors and works by boosting immune response to the cells carrying that protein,” Clay said. “From there, we gave the drug to 15 patients in a phase I study using the vaccine.”

The researchers found that when multiple doses of the denileukin diftitox were given, immune response to the vaccine was enhanced in these patients.

“This is encouraging. The next step will be to develop better drugs that support vaccines by enhancing the immune response they depend on to work,” Clay said. “It’s a concept that can be applied to any type of solid tumor, which has huge implications for cancer research.”

Vaccines are being used in clinical trials across the country to treat many malignancies, including lung cancer, brain tumors and colorectal cancer.

Source: Duke University Medical Center

Related stories:

FSU researcher using computers to hone cancer-fighting strategies
A Florida State University faculty member who uses computational techniques to evaluate a new class of cancer-killing drugs is attracting worldwide attention from other researchers.
Cancer cells revert to normal at specific signal threshold, researchers find
Cancer starts when key cellular signals run amok, driving uncontrolled cell growth. But scientists at the Stanford University School of Medicine report that lowering levels of one cancer signal under a specific threshold reverses this process in mice, returning tumor cells to their normal, healthy state. The finding could help target cancer chemotherapy to tumors while minimizing side effects for the body's healthy cells.
Cancer 'cure' in mice to be tested in humans
Scientists at Wake Forest University Baptist Medical Center are about to embark on a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice.
Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show
(Taking advantage of the fact that the intestines have a separate immune system from the rest of the body, scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have found a way to immunize mice against the development of metastatic disease.
Math could help cure leukemia
When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer.


Patient's own infection-fighting T cells put late-stage melanoma into long-term remission
Case is first to show safety and effectiveness of using cloned cells alone to kill tumors
Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.
UF scientists to work with German firm in prostate cancer treatment research
University of Florida department of urology officials signed an agreement Tuesday to collaborate with the German biopharmaceutical company CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment.
Weight loss after gastric bypass surgery may protect against infection and cancer
Another health benefit of bariatric weight-loss surgery may be a heightened immune defense against cancer and infections, a new study suggests. The results will be presented at The Endocrine Society's 90th Annual Meeting in San Francisco.

News discussion:

Medicine & Health news